# 1,2,4 OXADIAZOL 3 YL ARYLMETHANONES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

## Abstract
There are disclosed novel compounds having the formula

## Claims
1. A compound having the formula I where X is independently hydrogen, halogen F, Cl, Br or I , loweralkyl or loweralkoxy and R is CN, CONH₂, an optical antipode thereof, or a pharmaceutically acceptable acid addition salt thereof.

## Description
This invention relates to novel compounds of the formula Unless otherwise stated or indicated, the term loweralkyl donates a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said loweralkyl include methyl, ethyl, n propyl, iso propyl, n butyl, iso butyl, sec butyl, t butyl and straight and branched chain pentyl and hexyl. Unless otherwise stated or indicated, the term loweralkoxy denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms. Examples of said loweralkoxy include methoxy, ethoxy, n propoxy, iso propoxy, n butoxy, iso butoxy, sec butoxy, t butoxy and straight and branched chain pentoxy and hexoxy. Unless otherwise stated or indicated, the term halogen shall mean fluorine, chlorine, bromine or iodine. The compounds of the present invention are prepared by following one or more of the steps described below. Throughout the description of the synthetic steps, the definitions of X, R, R₁, R₂ and R₃ and n are as given above unless otherwise stated or indicated. A compound of Formula III below is prepared by a cyclo addition reaction between a compound of Formula II and malononitrile. Typically, said cyclo addition reaction is conducted at a temperature of 100 150 C in a suitable medium including aromatic hydrocarbons such as toluene, xylene or the like. A compound of Formula IV below is prepared by reacting compound III with concentrated sulfuric acid and then reacting the resultant product with water. The first step is typically conducted by preparing a solution of compound III in a large excess of concentrated e.g. 98 sulfuric acid and stirring the solution at a temperature of 10 40 C. The second step is typically conducted by slowly pouring said solution into ice water at the end of the first step. A compound of Formula V below is prepared by reacting compound IV with isopropanol. Typically said reaction is conducted by preparing a solution of compound IV in excess isopropanol, saturating the solution with hydrogen chloride gas and stirring or refluxing the solution at a temperature of about 70 83 C Alternatively, compound V can also be prepared by reacting compound III with isopropanol in the presence of an acid such as hydrogen chloride and then reacting the resultant product with water. Typically, the first step is conducted by preparing a solution of compound III in excess dry isopropanol, saturating the solution with hydrogen chloride gas and stirring or refluxing the solution at a temperature of about 70 83 C. The second step is typically conducted by pouring said solution into cold water at the end of the first step. A compound of Formula VI below is prepared by hydrolyzing comound V. Said hydrolysis is typically conducted by preparing a solution of compound V in excess concentrated sulfuric acid, stirring the solution at a temperature of 0 30 C and thereafter pouring it into ice water. A compound of Formula VII below is prepared by reacting compound III with ethanethiol and hydrogen chloride in tetrahydrofuran. Typically said reaction is conducted by preparing a solution of compound III and ethanethiol in tetrahydrofuran, saturating the solution with hydrogen chloride gas and stirring the solution at a temperature between about 10 C and 10 C. A compound of Formula VIII below is prepared by a cyclo addition reaction between compound II and chloroacetonitrile. Said cyclo addition is conducted in substantially the same manner as STEP A. A compound of Formula IX below is prepared by reacting compound VIII with phenyl mercaptan. Said reaction is usually conducted in the presence of a base such as triethylamine, pyridine, sodium hydride or the like in a suitable solvent including acetone, ethereal compounds such as diethyl ether, tetrahydrofuran, dioxane or the like, and dimethylformamide at a temperature of about 20 60 C. A compound of Formula X below is prepared by oxidizing compound IX with a suitable peroxy compound such as, for instance, m chloroperoxybenzoic acid. Typically, said oxidation reaction is conducted in a suitable solvent such as dichloromethane at a low temperature of from about 80 C to about 60 C. A compound of Formula XI below is prepared by reacting compound VIII with an amine or ammonia of the formula HNR₁R₂. Typically, when said amine is a gas as in the case of dimethylamine, the amine gas is bubbled into a suitable solvent including alcohols such as methanol, ethanol and propanol, ethereal compounds such as diethyl ether, tetrahydrofuran and dioxane and mixtures thereof, in order to saturate the solvent with the amine and then the resultant saturated solution is added to a solution of compound VI in a suitable solvent such as those mentioned above. When said amine is a liquid, the reaction mixture is prepared simply by dissolving the two reactants in a suitable solvent such as those mentioned above. The reaction is usually conducted at a temperature of about 20 100 C. A compound of Formula XII below is prepared by reacting compound VIII with morpholine. Said reaction is conducted in substantially the same manner as described in STEP J. A compound of Formula XIII below is prepared by reacting compound VIII with a compound of Formula XIV. Said reaction is conducted in substantially the same manner as described in STEP J. The compounds of the present invention are useful as antihypertensive agents due to their ability to depress blood pressure in mammals. Antihypertensive activity is measured in the spontaneous hypertensive rat by the indirect tail cuff method described in Methods in Pharmacology , A. Schwartz, Ed., Vol. I, Appleton Century Crofts, New York, N.Y., 1971, p.135. In this procedure a group of five animals are treated orally for three days with the test compound in relation to a control group of the same number. The drop in blood pressure is measured on the third day following administration. The antihypertensive activities of some of the compounds, expressed as a decrease in mean arterial blood pressure in mm Hg , are given in Table I along with the activity of a standard compound. The compounds of the present invention are also useful as analgesic agents due to their ability to alleviate pain in mammals. The activity of the compounds is demonstrated in the 2 phenyl 1,4 benzoquinone induced writhing test in mice, a standard assay for analgesia Proc. Soc. Exptl. Biol. Med., The compounds of the present invention are also useful as antiinflammatory agents due to their ability to suppress inflammation in mammals. The activity of the compounds is demonstrated in the carrageenin induced rat paw edema antiinflammatory assay Proc. Soc. Exptl. Biol. Med., III 544 1962 , J. Pharmacol. Exp., Effective quantities of the compounds of the invention may be administered to a patient by any of the various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free base final products, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like. Acids useful for preparing the pharmaceutically acceptable acid addition salts of the invention include inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as organic acids such as tartaric, citric, acetic, succinic, maleic, furamic and oxalic acids. The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets. For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5 of active compound, but may be varied depending upon the particular form and may conventiently be between 4 to about 70 of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0 300 milligrams of active compound. The tablets, pills, capsules, troches and the like may also contain the following ingredients a binder such as micro crystalline cellulose, gum tragacanth or gelatin an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, cornstarch and the like a lubricant such as magnesium stearate or Sterotex a glidant such as colloidal silicon dioxidel and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as pepperment, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non toxic in the amounts used. For the purposes of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1 of active compound, but may be varied to be between 0.5 and about 30 of the weight thereof. The amount of active compound in such compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound. The solutions or suspension may also include the following components a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents antibacterial agents such as benzyl alcohol or methyl parabens antioxidants such as ascorbic acid or sodium bisulfite chelating agents such as ethylenediaminetetraacetic acid buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in disposable syringes or multiple dose vials made of glass or plastic. Examples of the compounds of this invention include The following examples are given for illustrative purposes and are not to be considered as limiting the invention disclosed herein. All temperatures are given in degrees Celcius. A mixture of 15 g of chloroisonitrosoacetophenone, 54 g of malononitrile and 500 ml of toluene was refluxed with mechanical stirring under N₂ for 6 hours. The resulting mixture was stirred at room temperature overnight. The resulting suspension was decanted and the solids washed with toluene. The toluene was removed A mixture of 4 fluorophenylglyoxylohydroxamyl chloride 121 g and malononitrile 396 g was dissolved in toluene 2600 ml and refluxed under N₂ for 20 hours. The toluene was removed A mixture of 38 g of 4 chlorophenylglyoxylohydroxamyl chloride and 112 g of malononitrile in one liter of toluene was refluxed for 48 hours under N₂. The cooled mixture was filtered and concentrated A mixture of 125 g of 4 tolylglyoxylohydroxamyl chloride, 420 g of malononitrile and 3000 ml toluene was refluxed for 18 hours under N₂. The cooled mixture was filtered and concentrated. The residue was taken up in Et₂O, washed with water 8x and brine, and dried over MgSO₄. Concentration to about 200 ml and cooling precipitated 33.2 g of a solid, m.p. 75 78 . A solution of this material in CH₂Cl₂ 1000 ml was stirred with and decanted from 30 g of silica gel. Concentration gave 27.3 g 19 of a solid, m.p. 76 78 . A mixture of 4 methoxphenylglyoxylohydroxamyl chloride 170 g , malononitrile 335 g and toluene 2500 ml was refluxed under N₂ for 20 hours. The toluene was removed A solution of 5.0 g of 3 benzoyl 1,2,4 oxadiazol 5 yl acetonitrile in 50 ml 98 H₂SO₄ was stirred at room temperature overnight. The resulting solution was added slowly to a liter of ice water with mechanical stirring to precipitate a solid. The collected solid was washed with excess water and dried at 90 under high vacuum to give 4.9 g 90 of a powder, m.p. 155.5 157.5 . A solution of 3 4 fluorobenzoyl 1,2,4 oxadiazol 5 yl acetonitrile 5.0 g in 98 H₂SO₄ 50 ml was stirred at room temperature for 3 hours. The resulting solution was added slowly to a liter of ice water with mechanical stirring. The precipitated solid was collected by filtration and washed with water 5 x 300 ml and cold isopropanol 3 x 150 ml . The amide was dried in vacuum to yield 5.2 g 96 of a powder, m.p. 197 199 . A mixture of 2.8 g of 3 4 chlorobenzoyl 1,2,4 oxadiazol 5 yl acetonitrile and 25 ml of 98 H₂SO₄ was stirred at room temperature overnight. The resulting solution was added slowly to 500 ml of ice water with mechanical stirring to precipitate a solid. The collected solid was washed with excess water and dried A mixture of 23 g of 3 4 toluoyl 1,2,4 oxadiazol 5 yl acetonitrile and 200 ml of 98 H₂SO₄ was stirred at room temperature overnight. The resulting solution was added slowly to 3000 ml of ice water with mechanical stirring to precipitate a solid. The collected solid was washed with excess water and 600 ml of cold isopropanol, and dried A solution of 3 4 methoxybenzoyl 1,2,4 oxadiazol 5 yl acetonitrile 5.0 g in 98 H₂SO₄ 50 ml was stirred at room temperature for 3 hours. The resulting solution was added slowly to ice water 500 ml with stirring. The precipitated solid was collected by filtration, and washed with water 5 x 300 ml and isopropanol 25 ml . The crude dry amide 3.6 g was crystallized from EtOH 100 ml to yield 2.6 g 48 of needles, m.p. 149 150 . A mixture of 9.2 g of 3 benzoyl 1,2,4 oxadiazol 5 yl acetamide in 300 ml isopropanol was saturated with HCl gas. The resulting mixture was warmed to 70 and maintained there for 11 hours. The resulting cooled mixture was filtered and diluted with 400 ml water. Extraction with Et₂O 3x 300 ml , washing the organics with a saturated NaHCO₃ solution, drying over MgSO₄, filtration and concentration gave 10.1 g of an oil. Purification of 9.8 g of this oil by high pressure liquid chromatography with 20 hexane CH₂Cl₂ used as an eluent gave 7.0 g 64 of an oil. A mixture of 19.6 g of 3 4 fluorobenzoyl 1,2,4 oxadiazol 5 yl acetronitrile and isopropanol 500 ml was saturated with HCl gas. The resulting solution was refluxed for 6 hours, cooled, and poured into cold H₂O 1000 ml with stirring. THe aqueous mixture was extracted with Et₂O 4 x 200 ml . The organics were washed with water until neutral, dilute NaHCO₃ and saturate NaCl, dried over Na₂SO₄, and concentrated A mixture of 7.2 g of 3 4 chlorobenzoyl 1,2,4 oxadiazol 5 yl acetamide and 200 ml of anhydrous isopropanol was saturated with HCl gas. The resulting solution was warmed at about 70 overnight. The cooled mixture was filtered, diluted with water and extracted with Et₂O. The extracts were washed with saturated NaHCO₃ solution, dried over MgSO₄ and concentrated to give 8.1 g of an oil. Purification by HPLC with 20 hexane CH₂Cl₂ as an eluent gave 5.9 g 71 of an oil. A mixture of 17 g of 3 4 toluoyl 1,2,4 oxadiazol 5 yl acetamide and 500 ml of isopropanol was saturated with HCl gas. The resulting solution was refluxed overnight. The cooled mixture was filtered, diluted with water 700 ml and extracted with Et₂O 3x . The organics were washed with saturated NaHCO₃ solution, dried over MgSO₄, and concentrated to an oil. This material was purified by high pressure liquid chromatography with 15 ethyl acetate hexane as an eluent to give 11.2 g 56 of an oil. A mixture of 3 4 methoxybenzoyl 1,2,4 oxadiazol 5 yl acetonitrile 39 g in dry isopropanol 1 liter was saturated with HCl gas. The resulting solution was refluxed for 5 hours, cooled, and poured into cold water 2 liters with stirring. The aqueous mixture was extracted with Et₂O 3 x 800 ml . The organics were washed with water 4 x 1 liter until neutral and saturated NaCl, dried over Na₂SO₄, and concentrated To a flask containing 8.6 g of isopropyl 3 benzoyl 1,2,4 oxadiazol 5 yl acetate, which had been cooled in an ice bath, was added 50 ml of cold 97 sulfuric acid. This mixture was swirled continuously for three minutes. The resultant solution was poured gradually into one liter of ice water with mechanical stirring to precipitate the product. The solid was collected by filtration, washed with excess water and dried A solution of isopropyl 3 4 fluorobenzoyl 1,2,4 oxadiazol 5 yl acetate 6.2 g in 97 H₂SO₄ 40 ml was stirred at room temperature for 15 minutes. The resulting solution was added slowly to a liter of ice water with mechanical stirring. The precipitated solid was collected by filtration and washed with water 5 x 300 ml . Drying under vacuum gave 4.4 g of a powder. Recrystallization from 25 hexane acetone gave 2.5 g 47 of crystals, m.p. 146 148 . To a flask containing 5.2 g of isopropyl 3 4 chlorobenzoyl 1,2,4 oxadiazol 5 yl acetate was added 35 ml of cold concentrated H₂SO₄. The resulting mixture was stirred and swirled for 15 minutes. The resulting solution was poured slowly into mechanically stirred ice water to precipitate the product. The solid was collected by filtration, washed with excess water and dried under vacuum for 48 hours at room temperature to give 3.9 g of a solid. Recrystallization from acetone hexane gave 2.5 g 56 of a solid, m.p. 136 137 . To a flask containing 7.0 g of isopropyl 3 4 toluoyl 1,2,4 oxadiazol 5 yl acetate was added 50 ml of cold concentrated sulfuric acid. This mixture was swirled and stirred for 10 minutes. The resulting solution was poured gradually into one liter of ice water with mechanical stirring to precipitate the product. The solid was collected by filtration, washed with water and dried Finely powdered isopropyl 3 4 methoxybenzoyl 1,2,4 oxadiazol 5 yl acetate 13.5 g was added in portions over 15 minutes to concentrated H₂SO₄ 1000 ml with mechanical stirring. The mixture was stirred an additional 15 minutes until the ester dissolved. The resulting solution was added slowly to ice water 6 liters with stirring. The precipitated solid was filtered and dissolved in Et₂O 1500 ml . The organic phase was washed with water until neutral, saturated NaCl, dried over Na₂SO₄, and concentrated A solution of 9.7 g of 3 benzoyl 1,2,4 oxadiazol 5 yl acetonitrile in 250 ml of dry tetrahydrofuran was cooled to 25 . After adding 3.5 ml of ethanethiol, the solution was saturated with HCl gas by continuously bubbling for 15 minutes. The resulting solution was brought to 0 and maintained there for 3 hours. The cold solution was poured into 500 ml of toluene and steam was bubbled directly into the mixture until 200 ml of water had condensed without cooling . The layers were separated and the organics were washed with water and saturated NaCl solution and dried over MgSO₄. Filtration and concentration gave 7 g of an oil. Purification by high pressure liquid chromatography with 11 hexane CH₂Cl₂ used as an eluent gave 4.5 g 31 of an oil. A solution of 11.4 ml of triethylamine in 30 ml Et₂O was added dropwise to a solution consisting of 9.0 g of 3 benzoyl 5 chloromethyl 1,2,4 oxadiazole, 4.2 ml of thiophenol, 20 ml of acetone and 80 ml of Et₂O at room temperature. The resulting mixture was stirred for one hour. The reaction mixture was diluted with Et₂O, washed with 5 HCl 2x , water 2x and brine, and dried over MgSO₄. Concentration gave 11.5 g of an oil. Purification by high pressure liquid chromatography with 70 CH₂Cl₂ hexane as an eluent yielded 10.3 g 84 of an oil. A solution of 8.1 ml of triethylamine in 30 ml Et₂O was added to a solution of 7.5 g of 3 4 chlorobenzoyl 5 chloromethyl 1,2,4 oxadiazole and 3.0 ml of thiophenol in 20 ml of acetone and 80 ml of Et₂O at room temperature. This mixture was stirred for one hour. The reaction mixture was diluted with Et₂O, washed with 5 HCl 2x and brine, and dried over MgSO₄. Concentration gave 9.0 g of an oil. Purification by high pressure liquid chromatography with 70 CH₂Cl₂ hexane as an eluent yielded 6.0 g 62 of an oil. A solution of 13.4 ml of triethylamine in 35 ml Et₂O was added dropwise to a solution of 11.4 g of 5 chloromethyl 3 4 toluoyl 1,2,4 oxadiazole and 4.9 ml of thiophenol in 25 ml acetone and 100 ml Et₂O at room temperature. The resulting mixture was stirred for one hour. The reaction mixture was diluted with Et₂O, washed with 5 HCl 2x , water 2x , and brine, and dried over MgSO₄. Concentration gave 13.2 g of an oil. Purification by high pressure liquid chromatography with 70 CH₂Cl₂ hexane as an eluent yielded 11.0 g 79 of an oil. A solution of 5.5 g of A solution of 5.8 g of A solution of 5.14 of A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 fluorophenylmethanone 4.8 g, in 50 Et₂O MeOH 300 ml at 5 was saturated with dimethylamine gas. The resulting solution was allowed to warm to room temperature and stirred 16 hours. The volatiles were evaporated A solution of the amine in 50 Et₂O CH₂Cl₂ 20 ml was added dropwise to a solution of maleic acid 1,2 g, 10 mmol in Et₂O 250 ml . The precipitated salt was filtered and recrystallized from isopropanol 200 ml to yield 2.4 g 33 of crystals, m.p. 158 160 . Morpholine 5.5 ml was added to a solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 fluorophenylmethanone 4.8 g in 50 acetone Et₂O 200 ml . The resulting solution was stirred at room temperature for 15 hours. The mixture was filtered and the filtrate concentrated A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 fluorophenylmethanone 6.0 g, in Et₂O 160ml was added to a solution of N beta hydroxyethylpiperazine 8.1 g, in MeOH 200 ml . The resulting mixture was stirred at room temperature for 3 days. The solution was concentrated A solution of the amine 4.0 g in CH₂Cl₂ 15 ml was added dropwise to a solution of maleic acid 3.1 g in Et₂O 500 ml . The precipitated salt was filtered and recrystallized from ethyl acetate 480 ml to yield 5.0 g 35 of spherical crystals, m.p. 121 122 . A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 fluorophenylmethanone 4.8 g in acetone 100 ml was added to a solution of N phenylpiperazine 9.2 ml in Et₂O 100 ml . The resulting mixture was stirred at room temperature for 24 hours. The mixture was filtered and the filtrate concentrated A solution of 2.4 g of 5 chloromethyl 1,2,4 oxadiazol 3 yl phenylmethanone in 50 ml of tetrahydrofuran was added to a solution of 7.0 g of N 2,3,4 trimethoxybenzylpiperazine in 50 ml of CH₃OH. After stirring the mixture at room temperature for 4 days, it was concentrated to a residue. This material was flash chromatographed with used as an eluent to give 3.8 g of an oil. A solution of this compound in 70 ml of Et₂O was added to a solution of 2.6 g of maleic acid in 400 ml Et₂O. The collected solid was recrystallized from ethyl acetate to give 4.5 g 60 of a solid, m.p. 102 105 . A solution of 7.5 g of 2,3,4 trimethoxybenzylpiperazine in 50 ml of CH₃OH was added to a soltuion of 2.9 g of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 tolylmethanone in 50 ml of tetrahydrofuran. The resulting mixture was stirred at room temperature for 3 days. Concentration gave a residue which was flash chromatographed, with 1 2 ethyl acetate hexane used as an eluent to give 4.1 g of an oil. This was converted to its dimaleate salt in Et₂O and recrystallized from ethyl acetate to give 4.5 g 54 of a solid, m.p. 129 130 . A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl phenylmethanone 2.22 g in tetrahydrofuran 20 ml was added to a solution of N benzhydrylpiperazine 6.3 g in MeOH 50 ml . The reaction solution was stirred at room temperature for 3 days. The volatiles were evaporated to give a residue which was flash chromatographed 25 ethyl acetate hexane to give 4.6 g of an oil. A solution of the amine in Et₂O 50 ml was added to a solution of maleic acid 2.6 g in Et₂O 500 ml . The salt was filtered and recrystallized from ethyl acetate 350 ml to yield 3.2 g 48 of crystals, m.p. 133 135 . A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 fluorophenylmethanone 2.1 g in tetrahydrofuran 20 ml was added to a solution of N benzhydrylpiperazine 5.5 g in MeOH 50 ml . The reaction solution was stirred at room temperature for 3 days. The volatiles were evaporated to give a residue which was flash chromatographed 25 ethyl acetate hexane to give 4.2 g of an oil. A solution of the amine in Et₂O 40 ml was added to a solution of maleic acid 2.2 g in Et₂O 500 ml . The precipitated salt was filtered and recrystallized from EtOAc 200 ml to yield 3.2 g 53 of dense crystals, m.p. 146 148 . A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 methoxyphenylmethanone 2.5 g in tetrahydrofuran 20 ml was added to a solution of N benzhydrylpiperazine 6.3 g in MeOH 50 ml . The reaction soltuion was stirred at room temperature for 3 days. The volatiles were evaporated to give a residue which was flash chromatographed 25 ethyl acetate hexane to give 4.4 g of an oil. A solution of the amine in CH₂Cl₂ 20 ml was added to a solution of maleic acid 2.3 g in Et₂O 700 ml . The precipitated salt was filtered and recrystallized from ethyl acetate 300 ml to yield 4.4 g 63 of crystals, m.p. 142 144 . A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl phenylmethanone 3.0 g in tetrahydrofuran 20 ml was added to a solution of N 4,4 difluorobenzhydrylpiperazine 8.7 g in MeOH 50 ml . The reaction solution was stirred at room temperature for 3 days. The volatiles were evaporated to give a residue which was flash chromatographed 25 ethyl acetate hexane to give 6.5 g of a resin. The residue was purified by high pressure liquid chromatography 2 ethyl acetate CH₂Cl₂ to yield 4.1 g of an oil which solidified on standing. A solution of the amine in CH₂Cl₂ 30 ml was added to a solution of maleic acid 2.2 g in Et₂O 400 ml . The precipitated salt was filtered and recrystallized from acetonitrile 100 ml to yield 5.1 g 54 of crystals, m.p. 137 138 . A solution of 5 chloromethyl 1,2,4 oxadiazol 3 yl 4 methoxyphenylmethanone 2.5 g in tetrahydrofuran 20 ml was added to a solution of N 4,4 difluorobenzhydrylpiperazine 7.2 g, 25 mmol in MeOH 60 ml . The reaction solution was stirred at room temperature for 3 days. The volatiles were evaporated to give a residue which was flash chromatographed 25 ethyl acetate hexane to give 5.9 g of an oil. A solution of the amine in CH₂Cl₂ 40 ml was added to a solution of maleic acid 2.3 g in Et₂O 600 ml . The precipitated salt was filtered and recrystallized from acetonitrile 175 ml to yield 3.3 g 45 of a crystalline powder, m.p. 156 158 .